| Year |
Citation |
Score |
| 2020 |
Lin Z, Lin SY, Xie P, Lin CY, Rather GM, Bertino JR, Javanmard M. Rapid Assessment of Surface Markers on Cancer Cells Using Immuno-Magnetic Separation and Multi-frequency Impedance Cytometry for Targeted Therapy. Scientific Reports. 10: 3015. PMID 32080205 DOI: 10.1038/S41598-020-57540-7 |
0.303 |
|
| 2020 |
Rather GM, Szekely Z, Bertino JR. Abstract 2212: An antibody drug conjugate targeting activated matriptase, exhibits synergistic cytotoxicity with a PARP inhibitor, olaparib in triple negative breast cancer Immunology. 80: 2212-2212. DOI: 10.1158/1538-7445.Am2020-2212 |
0.338 |
|
| 2019 |
Rather GM, Lin SY, Lin H, Szekely Z, Bertino JR. A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma. Frontiers in Oncology. 9: 258. PMID 31024856 DOI: 10.3389/Fonc.2019.00258 |
0.318 |
|
| 2019 |
Goldfinger M, Xu M, Bertino JR, Cooper DL. Checking in on Lenalidomide in Diffuse Large B Cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. PMID 30926391 DOI: 10.1016/J.Clml.2019.02.012 |
0.376 |
|
| 2019 |
Chaturvedi S, Bertino JR. Methods to Study the Role of Methionine-Restricted Diet and Methioninase in Cancer Growth Control. Methods in Molecular Biology (Clifton, N.J.). 1866: 1-12. PMID 30725403 DOI: 10.1007/978-1-4939-8796-2_1 |
0.317 |
|
| 2019 |
Rather GM, Anyanwu M, Kerrigan JE, Scotto KW, Garbuzenko O, Minko T, Szekely Z, Bertino JR. Abstract 5213: A modified L-penetratin peptide targeting e2f-1, 2 and 3 is effective in combination with cisplatin or pemetrexed against prostate and lung cancer cell lines Cancer Research. 79: 5213-5213. DOI: 10.1158/1538-7445.Am2019-5213 |
0.312 |
|
| 2018 |
Shaik T, Rather GM, Bansal N, Minko T, Garbuzenko O, Szekely Z, Abali EE, Banerjee D, Kerrigan JE, Scotto KW, Bertino JR. Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer. Oncotarget. 9: 33249-33257. PMID 30279956 DOI: 10.18632/Oncotarget.26064 |
0.305 |
|
| 2018 |
Rather GM, Lin SY, Lin H, Banach-Petrosky W, Hirshfield KM, Lin CY, Johnson MD, Szekely Z, Bertino JR. Activated matriptase as a target to treat breast cancer with a drug conjugate. Oncotarget. 9: 25983-25992. PMID 29899836 DOI: 10.18632/Oncotarget.25414 |
0.309 |
|
| 2018 |
Chaturvedi S, Hoffman RM, Bertino JR. Exploiting methionine restriction for cancer treatment. Biochemical Pharmacology. 154: 170-173. PMID 29733806 DOI: 10.1016/J.Bcp.2018.05.003 |
0.326 |
|
| 2018 |
Wagner J, Kline CL, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino JR, et al. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. The Journal of Clinical Investigation. PMID 29533922 DOI: 10.1172/Jci96711 |
0.328 |
|
| 2018 |
Yu X, Kogan S, Chen Y, Tsang AT, Withers T, Lin H, Chen C, Moore DF, Bertino J, Chan C, Carpizo DR. Abstract B211: Cellular zinc homeostatic mechanisms function as an off switch for zinc metallochaperone-mediated reactivation of mutant p53 Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B211 |
0.332 |
|
| 2017 |
Morgan KM, Fischer BS, Lee FY, Shah JJ, Bertino JR, Rosenfeld J, Singh A, Khiabanian H, Pine SR. Gamma secretase inhibition by BMS-906024 enhances efficacy of paclitaxel in lung adenocarcinoma. Molecular Cancer Therapeutics. PMID 28978720 DOI: 10.1158/1535-7163.Mct-17-0439 |
0.344 |
|
| 2017 |
Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez-Rodriguez L, Aisner J, Aiken RD, Haffty BG, DiPaola RS, Saunders T, Zloza A, et al. First-in-human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28331050 DOI: 10.1158/1078-0432.Ccr-16-2658 |
0.326 |
|
| 2017 |
Kimani SG, Kumar S, Bansal N, Singh K, Kholodovych V, Comollo T, Peng Y, Kotenko SV, Sarafianos SG, Bertino JR, Welsh WJ, Birge RB. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity. Scientific Reports. 7: 43908. PMID 28272423 DOI: 10.1038/Srep43908 |
0.305 |
|
| 2017 |
Bertino JR, Szekely Z, Scotto KW. Studies of a novel modified E2F-targeted peptide with activity against castration-resistant prostate cancer. Journal of Clinical Oncology. 35: 205-205. DOI: 10.1200/Jco.2017.35.6_Suppl.205 |
0.331 |
|
| 2017 |
Rodriguez-Rodriguez L, Mehnert JM, Silk AW, Chan N, Malhotra J, Aisner J, Saunders T, Yu B, Dickerson S, Tarapore R, Allen JE, Stogniew M, Oster W, Kaufman H, Haffty BG, ... Bertino JR, et al. Clinical activity of the selective DRD2 antagonist ONC201, an imipridone, in metastatic endometrial cancer (mEC). Journal of Clinical Oncology. 35: 5592-5592. DOI: 10.1200/Jco.2017.35.15_Suppl.5592 |
0.35 |
|
| 2017 |
Ames TD, Sharik ME, Rather GM, Hochart G, Bonnel D, Linehan S, Stauber J, Wing RA, Jimeno JJ, Medina D, Bertino JR, Chesi M, Bergsagel PL. Translational Research of PT-112, a Clinical Agent in Advanced Phase I Development: Evident Bone Tropism, Synergy In Vitro with Bortezomib and Lenalidomide , and Potent Efficacy in the Vk*MYC Mouse Model of Multiple Myeloma Blood. 130: 1797-1797. DOI: 10.1182/Blood.V130.Suppl_1.1797.1797 |
0.313 |
|
| 2017 |
Wagner J, Kline CL, Zhou L, Zloza A, Chesson C, Newman J, Kaufman H, Bertino J, Stein M, El-Deiry W. Abstract 124: Imipridone ONC201 promotes intra-tumoral accumulation of CD3+/NK+ cells that contribute to its anti-tumor efficacy Cancer Research. 77: 124-124. DOI: 10.1158/1538-7445.Am2017-124 |
0.301 |
|
| 2016 |
Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, ... ... Bertino J, et al. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. PMID 27602582 DOI: 10.18632/Oncotarget.11814 |
0.314 |
|
| 2016 |
Tedeschi PM, Bansal N, Kerrigan JE, Abali EE, Scotto KW, Bertino JR. NAD+ Kinase as a Therapeutic Target in Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27582489 DOI: 10.1158/1078-0432.Ccr-16-1129 |
0.317 |
|
| 2016 |
Tedeschi PM, Scotto KW, Kerrigan J, Bertino JR. MTHFD2- a new twist? Oncotarget. 7: 7368-9. PMID 26848977 DOI: 10.18632/Oncotarget.7147 |
0.351 |
|
| 2016 |
Ferrari AC, DiPaola RS, Bertino JR, Kim IY, Stein MN, Sabaawy HE, Bartucci M. Patient stem cell (SC)-derived prostate cancer (PC) organoids (Org) to recreate clonal heterogeneity of PC foci and measure therapeutic response potential. Journal of Clinical Oncology. 34: 252-252. DOI: 10.1200/Jco.2016.34.2_Suppl.252 |
0.343 |
|
| 2016 |
Stein MN, Chan N, Silk AW, Fang B, Kaufman H, Haffty BG, Saunders T, Najmi S, Zheng L, Stogniew M, Allen JE, Oster W, Bertino JR, Mehnert JM. First-in-human trial of ONC201 in patients with refractory solid tumors. Journal of Clinical Oncology. 34: 2514-2514. DOI: 10.1200/Jco.2016.34.15_Suppl.2514 |
0.302 |
|
| 2015 |
Perkins J, Bertino JR. STIMULATION OF DIHYDROFOLATE REDUCTASE ACTIVITY BY p-CHLOROMERCURIBENZOATE. Biochemical and Biophysical Research Communications. 15: 121-6. PMID 26410903 DOI: 10.1016/0006-291X(64)90310-9 |
0.708 |
|
| 2015 |
Tedeschi PM, Lin H, Gounder M, Kerrigan JE, Abali EE, Scotto K, Bertino JR. Suppression of Cytosolic NADPH Pool by Thionicotinamide Increases Oxidative Stress and Synergizes with Chemotherapy. Molecular Pharmacology. 88: 720-7. PMID 26219913 DOI: 10.1124/Mol.114.096727 |
0.337 |
|
| 2015 |
Tedeschi PM, Vazquez A, Kerrigan JE, Bertino JR. Mitochondrial Methylenetetrahydrofolate Dehydrogenase (MTHFD2) Overexpression Is Associated with Tumor Cell Proliferation and Is a Novel Target for Drug Development. Molecular Cancer Research : McR. 13: 1361-6. PMID 26101208 DOI: 10.1158/1541-7786.Mcr-15-0117 |
0.321 |
|
| 2015 |
Bansal N, Mishra PJ, Stein M, DiPaola RS, Bertino JR. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells. Oncotarget. PMID 26036314 DOI: 10.18632/Oncotarget.4148 |
0.345 |
|
| 2015 |
DiFranco KM, Johnson-Farley N, Bertino JR, Elson D, Vega BA, Belinka BA, Kachlany SC. LFA-1-targeting Leukotoxin (LtxA; Leukothera®) causes lymphoma tumor regression in a humanized mouse model and requires caspase-8 and Fas to kill malignant lymphocytes. Leukemia Research. 39: 649-56. PMID 25850729 DOI: 10.1016/J.Leukres.2015.03.010 |
0.323 |
|
| 2015 |
Johnson-Farley N, Veliz J, Bhagavathi S, Bertino JR. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells. Leukemia & Lymphoma. 56: 2146-52. PMID 25373508 DOI: 10.3109/10428194.2014.981172 |
0.37 |
|
| 2015 |
Scott K, Tsang YH, Dogruluk T, Tedeschi P, Bertino J, Mills G. Abstract PR06: Functional prioritization of rare gene aberration drivers of cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-Pr06 |
0.305 |
|
| 2015 |
Bansal N, Wu L, Farley NJ, Tedeschi P, Bertino JR. Abstract 4208: The castrate resistant PC-3 cell line with neuroendocrine features is enriched in tumor initiating cells and is resistant to enzalutamide and abiraterone but sensitive to antimetabolites Cancer Research. 75: 4208-4208. DOI: 10.1158/1538-7445.Am2015-4208 |
0.349 |
|
| 2015 |
Morgan KM, Lee F, Michaud E, Bertino JR, Fischer BS, Pine SR. Abstract 2535: Synergistic anti-tumor activity of the Notch gamma secretase inhibitor BMS-906024 and paclitaxel in the treatment of lung adenocarcinoma Cancer Research. 75: 2535-2535. DOI: 10.1158/1538-7445.Am2015-2535 |
0.331 |
|
| 2015 |
Sabaawy HE, Bartucci M, Stein MN, Kim IY, Bertino JR, DiPaola RS, Ferrari A. Abstract C36: Patient-derived organoids from high-risk prostate cancer identify different biological subtypes and responsiveness to therapy Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C36 |
0.36 |
|
| 2014 |
Munshi PN, Lubin M, Bertino JR. 6-thioguanine: a drug with unrealized potential for cancer therapy. The Oncologist. 19: 760-5. PMID 24928612 DOI: 10.1634/Theoncologist.2014-0178 |
0.329 |
|
| 2014 |
Bertino JR, Johnson-Farley N, Bhagavathi S. Studies of the combination of ABT-199, a BH3 mimetic that specifically targets Bcl-2 in combination with chemotherapy and the proteosome inhibitor bortezomib in "double hit" lymphoma. Journal of Clinical Oncology. 32: e19507-e19507. DOI: 10.1200/Jco.2014.32.15_Suppl.E19507 |
0.329 |
|
| 2014 |
Markert E, Tedeschi P, Dolphi S, Hirshfield K, Bertino J, Oltvai Z, Vazquez A. Cell proliferation and tissue remodeling are major determinants of cancer metabolism and the response to drugs targeting metabolism Cancer & Metabolism. 2: P80. DOI: 10.1186/2049-3002-2-S1-P80 |
0.301 |
|
| 2014 |
Wu LY, Bansal N, Liu T, Berkman CE, Bertino JR. Abstract 214: Androgen resistance in prostate cancer is associated with an enrichment of stem-like cells Cancer Research. 74: 214-214. DOI: 10.1158/1538-7445.Am2014-214 |
0.31 |
|
| 2013 |
Tedeschi PM, Markert EK, Gounder M, Lin H, Dvorzhinski D, Dolfi SC, Chan LLY, Qiu J, DiPaola RS, Hirshfield KM, Boros LG, Bertino JR, Oltvai ZN, Vazquez A. Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells Cell Death and Disease. 4. PMID 24157871 DOI: 10.1038/Cddis.2013.393 |
0.311 |
|
| 2013 |
Xie X, Kerrigan JE, Minko T, Garbuzenko O, Lee KC, Scarborough A, Abali EE, Budak-Alpdogan T, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR. Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer. Cancer Biology & Therapy. 14: 742-51. PMID 23792570 DOI: 10.4161/Cbt.25184 |
0.315 |
|
| 2013 |
Hsieh YC, Tedeschi P, Adebisi Lawal R, Banerjee D, Scotto K, Kerrigan JE, Lee KC, Johnson-Farley N, Bertino JR, Abali EE. Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs. Molecular Pharmacology. 83: 339-53. PMID 23197646 DOI: 10.1124/Mol.112.080218 |
0.368 |
|
| 2013 |
Vazquez A, Tedeschi PM, Bertino JR. Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors. Cancer Research. 73: 478-82. PMID 23135910 DOI: 10.1158/0008-5472.Can-12-3709 |
0.302 |
|
| 2013 |
Bansal N, Mishra P, Cruz K, Bertino J. Abstract 996: Receptor tyrosine kinase AXL is upregulated in metformin resistant prostate cancer cells. Cancer Research. 73: 996-996. DOI: 10.1158/1538-7445.Am2013-996 |
0.315 |
|
| 2013 |
Tedeschi PM, Kerrigan J, Banerjee D, Bertino JR, Abali EE. Abstract 5536: NAD+ Kinase inhibition synergizes with ROS-inducing chemotherapies. Cancer Research. 73: 5536-5536. DOI: 10.1158/1538-7445.Am2013-5536 |
0.348 |
|
| 2013 |
Tedeschi PM, Markert EK, Gounder M, Lin H, Dolfi SC, Chan LL, Qiu J, Hirshfield KM, Boros LG, Bertino JR, Oltvai ZN, Vazquez A. Abstract C151: Contribution of serine, folate, and glycine metabolism to the ATP, NADPH, and purine requirements of cancer cells. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C151 |
0.309 |
|
| 2012 |
Bertino JR, Lubin M, Johnson-Farley N, Chan WC, Goodell L, Bhagavathi S. Lack of expression of MTAP in uncommon T-Cell lymphomas Clinical Lymphoma, Myeloma and Leukemia. 12: 306-309. PMID 23040436 DOI: 10.1016/J.Clml.2012.07.001 |
0.336 |
|
| 2012 |
Roussel B, Johnson-Farley N, Kerrigan JE, Scotto KW, Banerjee D, Felczak K, Pankiewicz KW, Gounder M, Lin H, Abali EE, Bertino JR. A second target of benzamide riboside: dihydrofolate reductase. Cancer Biology & Therapy. 13: 1290-8. PMID 22954684 DOI: 10.4161/Cbt.21786 |
0.376 |
|
| 2012 |
Barboza NM, Medina DJ, Budak-Alpdogan T, Aracil M, Jimeno JM, Bertino JR, Banerjee D. Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab. Cancer Biology & Therapy. 13: 114-22. PMID 22336911 DOI: 10.4161/Cbt.13.2.18876 |
0.363 |
|
| 2012 |
Xie X, Banerjee D, Minko T, Johnson-Farley N, Kerrigan JE, Ercikan-Abali E, Scotto KW, Bertino JR. Abstract 5689: Anti-E2F-1 PEGylated liposomal encapsulated peptide regresses human small cell lung cancer & lymphoma xenografts Cancer Research. 72: 5689-5689. DOI: 10.1158/1538-7445.Am2012-5689 |
0.341 |
|
| 2011 |
Bertino JR, Waud WR, Parker WB, Lubin M. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies. Cancer Biology & Therapy. 11: 627-32. PMID 21301207 DOI: 10.4161/Cbt.11.7.14948 |
0.336 |
|
| 2011 |
Bertino JR, Lee K, Johnson-Farley N, Lubin M. Abstract 3548: Selective targeting of pancreatic tumors lacking methylthioadenosine phosphorylase (MTAP) Cancer Research. 71: 3548-3548. DOI: 10.1158/1538-7445.Am2011-3548 |
0.331 |
|
| 2010 |
Bertino JR, Johnson-Farley N, Perez RP, Lubin A, Lubin M. Abstract 5393: Regression of a human T-cell leukemia lacking the methylthioadenosine phosphorylase (MTAP) gene without toxicity of 6-thioguanine (6TG) by pretreatment with methylthioadenosine (MTA) Cancer Research. 70: 5393-5393. DOI: 10.1158/1538-7445.Am10-5393 |
0.31 |
|
| 2010 |
Hsieh Y, Lawal RA, Scotto K, Banerjee D, Abali EE, Bertino JR. Abstract 4543: Targeting the NADPH binding site of dihydrofolate reductase for cancer therapy Cancer Research. 70: 4543-4543. DOI: 10.1158/1538-7445.Am10-4543 |
0.373 |
|
| 2010 |
Bansal N, Campbell N, Medina D, DiPaola R, Bertino JR, Sabaawy HE. Abstract 4279: Targeting Bmi1 in human prostate tumor initiating cells Cancer Research. 70: 4279-4279. DOI: 10.1158/1538-7445.Am10-4279 |
0.307 |
|
| 2010 |
Bertino JR, Lin S, Lin C. Abstract 2596: Targeted delivery of doxorubicin conjugated with anti-matriptase antibody to treat multiple myeloma Cancer Research. 70: 2596-2596. DOI: 10.1158/1538-7445.Am10-2596 |
0.364 |
|
| 2009 |
Longo-Sorbello GSA, Gao H, Mishra PJ, Kamen B, Soto A, Jimeno J, Aracil M, Paz MFPD, Bertino JR, Banerjee D. Heparin and Suramin Alter Plitidepsin Uptake Via Inhibition of GPCR Coupled Signaling Journal of Chemotherapy. 21: 550-557. PMID 19933047 DOI: 10.1179/Joc.2009.21.5.550 |
0.355 |
|
| 2009 |
Levitt MJ, Gharibo M, Strair R, Schaar D, Rubin A, Bertino JR. Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate. Journal of Chemotherapy (Florence, Italy). 21: 434-8. PMID 19622463 DOI: 10.1179/Joc.2009.21.4.434 |
0.355 |
|
| 2009 |
Hsieh YC, Skacel NE, Bansal N, Scotto KW, Banerjee D, Bertino JR, Abali EE. Species-specific differences in translational regulation of dihydrofolate reductase. Molecular Pharmacology. 76: 723-33. PMID 19570950 DOI: 10.1124/Mol.109.055772 |
0.778 |
|
| 2009 |
Budak-Alpdogan T, Bertino JR. Chemoprotection by transfer of resistance genes. Methods in Molecular Biology (Clifton, N.J.). 542: 661-704. PMID 19565927 DOI: 10.1007/978-1-59745-561-9_34 |
0.318 |
|
| 2009 |
Humeniuk R, Menon LG, Mishra PJ, Gorlick R, Sowers R, Rode W, Pizzorno G, Cheng YC, Kemeny N, Bertino JR, Banerjee D. Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Molecular Cancer Therapeutics. 8: 1037-44. PMID 19383847 DOI: 10.1158/1535-7163.Mct-08-0716 |
0.358 |
|
| 2009 |
Humeniuk R, Mishra PJ, Bertino JR, Banerjee D. Epigenetic reversal of acquired resistance to 5-fluorouracil treatment. Molecular Cancer Therapeutics. 8: 1045-54. PMID 19383845 DOI: 10.1158/1535-7163.Mct-08-0717 |
0.327 |
|
| 2009 |
Humeniuk R, Mishra PJ, Bertino JR, Banerjee D. Molecular targets for epigenetic therapy of cancer. Current Pharmaceutical Biotechnology. 10: 161-5. PMID 19199948 DOI: 10.2174/138920109787315123 |
0.312 |
|
| 2009 |
Budak-Alpdogan T, Chen B, Warrier A, Medina DJ, Moore D, Bertino JR. Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1232-40. PMID 19174488 DOI: 10.1158/1078-0432.Ccr-08-0810 |
0.336 |
|
| 2008 |
Bertino JR. Transfer of drug resistance genes into hematopoietic stem cells for marrow protection. The Oncologist. 13: 1036-42. PMID 18952565 DOI: 10.1634/Theoncologist.2008-0173 |
0.303 |
|
| 2008 |
Bertino JR. Implantable pump for long-term chemotherapy administration via the hepatic artery: has it fulfilled its promise? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4528-9. PMID 18824703 DOI: 10.1200/Jco.2008.18.0117 |
0.326 |
|
| 2007 |
Moskowitz CH, Hamlin PA, Gabrilove J, Bertino JR, Portlock CS, Straus DJ, Gencarelli AN, Nimer SD, Zelenetz AD. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 18: 1842-50. PMID 17872903 DOI: 10.1093/Annonc/Mdm341 |
0.336 |
|
| 2007 |
Humeniuk R, Menon LG, Mishra PJ, Saydam G, Longo-Sorbello GSA, Elisseyeff Y, Lewis LD, Aracil M, Jimeno J, Bertino JR, Banerjee D. Aplidin synergizes with cytosine arabinoside: Functional relevance of mitochondria in Aplidin-induced cytotoxicity Leukemia. 21: 2399-2405. PMID 17713546 DOI: 10.1038/Sj.Leu.2404911 |
0.361 |
|
| 2007 |
Bertino J, Fleisher M, Beumer JH, Chu E, Paolo Ad, Eng C, Extermann M, Gamelin E, Hurwitz H, Milano G, Salamone SJ, Shaw L. Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007 Clinical Colorectal Cancer. 6: 407-422. PMID 17539192 DOI: 10.1016/S1533-0028(11)70480-7 |
0.337 |
|
| 2007 |
Longo-Sorbello GS, Chen B, Budak-Alpdogan T, Bertino JR. Role of pemetrexed in non-small cell lung cancer. Cancer Investigation. 25: 59-66. PMID 17364559 DOI: 10.1080/07357900601130748 |
0.367 |
|
| 2007 |
Dabrowska M, Hendrikx PJ, Skierski J, Malinowska M, Bertino JR, Rode W. EGFP fluorescence as an indicator of cancer cells response to methotrexate. European Journal of Pharmacology. 555: 93-9. PMID 17141212 DOI: 10.1016/J.Ejphar.2006.10.052 |
0.306 |
|
| 2006 |
Russo AJ, Magro PG, Hu Z, Li WW, Peters R, Mandola J, Banerjee D, Bertino JR. E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents. Cancer Research. 66: 7253-60. PMID 16849574 DOI: 10.1158/0008-5472.Can-05-3725 |
0.771 |
|
| 2006 |
Bertino JR, Donohue DM, Simmons B, Gabrio BW, Silber R, Huennekens FM. THE "INDUCTION" OF DIHYDROFOLIC REDUCTASE ACTIVITY IN LEUKOCYTES AND ERYTHROCYTES OF PATIENTS TREATED WITH AMETHOPTERIN. The Journal of Clinical Investigation. 42: 466-75. PMID 16695899 DOI: 10.1172/JCI104735 |
0.563 |
|
| 2005 |
Budak-Alpdogan T, Banerjee D, Bertino JR. Hematopoietic stem cell gene therapy with drug resistance genes: an update. Cancer Gene Therapy. 12: 849-63. PMID 16037821 DOI: 10.1038/Sj.Cgt.7700866 |
0.321 |
|
| 2005 |
Skacel N, Menon LG, Mishra PJ, Peters R, Banerjee D, Bertino JR, Abali EE. Identification of amino acids required for the functional up-regulation of human dihydrofolate reductase protein in response to antifolate Treatment. The Journal of Biological Chemistry. 280: 22721-31. PMID 15817466 DOI: 10.1074/Jbc.M500277200 |
0.78 |
|
| 2005 |
Bertino JR, Roger S, Arnold R, Mecide G, Dale S. Accelerated R-COP:A Pilot Study for the Treatment of Follicular Lymphoma. Blood. 106: 4747-4747. DOI: 10.1182/Blood.V106.11.4747.4747 |
0.327 |
|
| 2004 |
Capiaux GM, Budak-Alpdogan T, Alpdogan O, Bornmann W, Takebe N, Banerjee D, Maley F, Bertino JR. Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene Cancer Gene Therapy. 11: 767-773. PMID 15359285 DOI: 10.1038/Sj.Cgt.7700683 |
0.79 |
|
| 2004 |
Budak-Alpdogan T, Alpdogan O, Banerjee D, Wang E, Moore MA, Bertino JR. Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 574-84. PMID 15336657 DOI: 10.1016/J.Ymthe.2004.06.115 |
0.323 |
|
| 2004 |
Li W, Su D, Mizobuchi H, Martin DS, Gu B, Gorlick R, Cole P, Bertino JR. Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells. Oncology Research. 14: 373-9. PMID 15301428 DOI: 10.3727/0965040041292332 |
0.319 |
|
| 2004 |
Magro PG, Russo AJ, Li WW, Banerjee D, Bertino JR. p14ARF expression increases dihydrofolate reductase degradation and paradoxically results in resistance to folate antagonists in cells with nonfunctional p53. Cancer Research. 64: 4338-45. PMID 15205349 DOI: 10.1158/0008-5472.Can-03-1045 |
0.76 |
|
| 2004 |
Banerjee D, Saydam G, Menon LG, Longo GS, Medina D, Strair R, Jimeno J, Erba E, Grossi A, Kapers GJL, Martinez N, Bertino J. Preclinical Investigations Demonstrate Effectiveness of Aplidin in Acute Leukemias and Lymphomas and Provide the Basis for Further Clinical Studies. Blood. 104: 4496-4496. DOI: 10.1182/Blood.V104.11.4496.4496 |
0.384 |
|
| 2004 |
Mishra PJ, Longo GS, Menon LG, Abali E, Banerjee D, Bertino J. A 3′ UTR Single Nucleotide Polymorphism 829C→T in Dihydrofolate Reductase Gene Results in an Increase in DHFR Protein Level and MTX Resistance. Blood. 104: 2084-2084. DOI: 10.1182/Blood.V104.11.2084.2084 |
0.365 |
|
| 2003 |
Capiaux GM, Budak-Alpdogan T, Takebe N, Mayer-Kuckuk P, Banerjee D, Maley F, Bertino JR. Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil. Human Gene Therapy. 14: 435-46. PMID 12691609 DOI: 10.1089/104303403321467207 |
0.784 |
|
| 2002 |
Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochimica Et Biophysica Acta. 1587: 164-73. PMID 12084458 |
0.791 |
|
| 2002 |
Banerjee D, Bertino JR. Myeloprotection with drug-resistance genes. The Lancet. Oncology. 3: 154-8. PMID 11902501 DOI: 10.1016/S1470-2045(02)00678-2 |
0.336 |
|
| 2002 |
Mayer-Kuckuk P, Banerjee D, Malhotra S, Doubrovin M, Iwamoto M, Akhurst T, Balatoni J, Bornmann W, Finn R, Larson S, Fong Y, Gelovani Tjuvajev J, Blasberg R, Bertino JR. Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression. Proceedings of the National Academy of Sciences of the United States of America. 99: 3400-5. PMID 11891321 DOI: 10.1073/Pnas.062036899 |
0.326 |
|
| 2001 |
Takebe N, Zhao SC, Ural AU, Johnson MR, Banerjee D, Diasio RB, Bertino JR. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Therapy. 8: 966-973. PMID 11781659 DOI: 10.1038/Sj.Cgt.7700393 |
0.354 |
|
| 2001 |
Sapse AM, Capiaux GM, Bertino JR. Examination of the reduced affinity of the thymidylate synthase G52S mutation for FdUMP by ab initio and semi-empirical studies. Molecular Medicine (Cambridge, Mass.). 7: 200-4. PMID 11471557 DOI: 10.1007/Bf03401954 |
0.755 |
|
| 1999 |
Banerjee D, Tong Y, Liu-Chen X, Capiaux G, Ercikan-Abali EA, Takebe N, O'Connor OA, Bertino JR. Protection of bone marrow cells from toxicity of chemotherapeutic agents targeted toward thymidylate synthase by transfer of mutant forms of human thymidylate synthase cDNA. Progress in Experimental Tumor Research. 36: 107-14. PMID 10386068 DOI: 10.1159/000061991 |
0.771 |
|
| 1999 |
Chou TC, Zhang XG, Harris CR, Kuduk SD, Balog A, Savin KA, Bertino JR, Danishefsky SJ. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proceedings of the National Academy of Sciences of the United States of America. 95: 15798-802. PMID 9861050 DOI: 10.1073/Pnas.95.26.15798 |
0.334 |
|
| 1998 |
Casper ES, Waltzman RJ, Schwartz GK, Sugarman A, Pfister D, Ilson D, Woodruff J, Leung D, Bertino JR. Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Investigation. 16: 442-6. PMID 9774950 DOI: 10.3109/07357909809011697 |
0.355 |
|
| 1998 |
Chou TC, Zhang XG, Balog A, Su DS, Meng D, Savin K, Bertino JR, Danishefsky SJ. Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proceedings of the National Academy of Sciences of the United States of America. 95: 9642-7. PMID 9689134 DOI: 10.1073/Pnas.95.16.9642 |
0.355 |
|
| 1998 |
Tong Y, Liu-Chen X, Ercikan-Abali EA, Capiaux GM, Zhao SC, Banerjee D, Bertino JR. Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells. The Journal of Biological Chemistry. 273: 11611-8. PMID 9565579 |
0.792 |
|
| 1998 |
Flasshove M, Banerjee D, Leonard JP, Mineishi S, Li MX, Bertino JR, Moore MA. Retroviral transduction of human CD34+ umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA. Human Gene Therapy. 9: 63-71. PMID 9458243 DOI: 10.1089/Hum.1998.9.1-63 |
0.328 |
|
| 1997 |
Ercikan-Abali EA, Banerjee D, Waltham MC, Skacel N, Scotto KW, Bertino JR. Dihydrofolate reductase protein inhibits its own translation by binding to dihydrofolate reductase mRNA sequences within the coding region Biochemistry. 36: 12317-12322. PMID 9315871 DOI: 10.1021/Bi971026E |
0.756 |
|
| 1997 |
Zhao SC, Banerjee D, Mineishi S, Bertino JR. Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA. Human Gene Therapy. 8: 903-9. PMID 9195212 DOI: 10.1089/Hum.1997.8.8-903 |
0.314 |
|
| 1996 |
Minsky BD, Conti J, Cohen AM, Kelsen DP, Saltz L, Guillem JG, Paty PP, Bass J, Bertino JR. Acute toxicity of neoadjuvant bolus 5-FU/methotrexate and leucovorin rescue followed by continuous infusion 5-FU plus pre-operative radiation therapy for rectal cancer Radiation Oncology Investigations. 4: 90-97. DOI: 10.1002/(Sici)1520-6823(1996)4:2<90::Aid-Roi7>3.0.Co;2-G |
0.316 |
|
| 1995 |
Almasan A, Yin Y, Kelly RE, Lee EY, Bradley A, Li W, Bertino JR, Wahl GM. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proceedings of the National Academy of Sciences of the United States of America. 92: 5436-40. PMID 7777526 DOI: 10.1073/Pnas.92.12.5436 |
0.317 |
|
| 1995 |
Li W, Fan J, Hochhauser D, Banerjee D, Zielinski Z, Almasan A, Yin Y, Kelly R, Wahl GM, Bertino JR. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proceedings of the National Academy of Sciences of the United States of America. 92: 10436-40. PMID 7479800 DOI: 10.1073/Pnas.92.22.10436 |
0.359 |
|
| 1995 |
Moni J, Yahalom J, Bertino J, O'Brien J, Portlock C, Straus D, Zelenetz A, Gomez E, Gulati S. 2038 Autologous bone marrow transplantation following high-dose chemotherapy with or without accelerated hyperfractionated total lymphoid irradiation for patients with refractory or relapsed Hodgkin's disease International Journal of Radiation Oncology*Biology*Physics. 32: 281. DOI: 10.1016/0360-3016(95)97941-S |
0.315 |
|
| 1992 |
Marsh JC, Durivage HJ, Davis C, O'Hollaren K, Pasquale DN, Simonich SA, Voynick IM, Bertino JR. Phase II study of pulse 5-fluoro-2'-deoxyuridine and leucovorin in advanced colorectal cancer patients previously treated with chemotherapy. American Journal of Clinical Oncology. 15: 115-8. PMID 1532470 DOI: 10.1097/00000421-199204000-00004 |
0.341 |
|
| 1991 |
Marsh JC, Bertino JR, Katz KH, Davis CA, Durivage HJ, Rome LS, Richards F, Capizzi RL, Farber LR, Pasquale DN. The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 9: 371-80. PMID 1999706 DOI: 10.1200/Jco.1991.9.3.371 |
0.337 |
|
| 1991 |
Crown JP, Gulati S, Straus DJ, Kolitz J, Heelan R, O'Brien J, Lee BJ, Portlock C, Bertino J. Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas. Investigational New Drugs. 9: 185-186. PMID 1874601 DOI: 10.1007/Bf00175086 |
0.348 |
|
| 1988 |
Prosnitz LR, Farber LR, Kapp DS, Scott J, Bertino JR, Fischer JJ, Cadman EC. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 6: 603-12. PMID 2451712 DOI: 10.1200/Jco.1988.6.4.603 |
0.79 |
|
| 1987 |
Portlock CS, Fischer DS, Cadman E, Lundberg WB, Levy A, Bobrow S, Bertino JR, Farber L. High-dose pulse chlorambucil in advanced, low-grade non-Hodgkin's lymphoma. Cancer Treatment Reports. 71: 1029-31. PMID 3677110 |
0.765 |
|
| 1987 |
Lin JT, Bertino JR. Trimetrexate: A second generation folate antagonist in clinical trial Journal of Clinical Oncology. 5: 2032-2040. PMID 2960788 DOI: 10.1200/Jco.1987.5.12.2032 |
0.306 |
|
| 1986 |
Jaffe HS, Cadman EC, Farber LR, Bertino JR. Pretreatment hematocrit as an independent prognostic variable in Hodgkin's disease. Blood. 68: 562-4. PMID 3730617 |
0.765 |
|
| 1985 |
Bertino JR, Srimatkandada S, Carman MD, Mini E, Jastreboff M, Moroson BA, Dube SK. Mechanisms of drug resistance in human leukemia. Haematology and Blood Transfusion. 29: 90-5. PMID 4029741 DOI: 10.1007/978-3-642-70385-0_22 |
0.344 |
|
| 1984 |
Carman MD, Schornagel JH, Rivest RS, Srimatkandada S, Portlock CS, Duffy T, Bertino JR. Resistance to methotrexate due to gene amplification in a patient with acute leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2: 16-20. PMID 6583326 DOI: 10.1200/Jco.1984.2.1.16 |
0.362 |
|
| 1984 |
Vera R, Bertino JR, Cadman E, Waldron JA. Malignant histiocytosis. Response to VP-16-213 and cytosine arabinoside. Cancer. 54: 991-3. PMID 6467142 DOI: 10.1002/1097-0142(19840915)54:6<991::Aid-Cncr2820540608>3.0.Co;2-R |
0.783 |
|
| 1984 |
Todd M, Cadman E, Spiro P, Bertino J, Farber L, Waldron J, Fischer D. A follow-up of a randomized study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma. Journal of Clinical Oncology. 2: 986-993. PMID 6206207 DOI: 10.1200/Jco.1984.2.9.986 |
0.353 |
|
| 1983 |
Cadman E, Bloom AF, Prosnitz L, Farber L, Vera R, Bertino J, Fischer D, Lawrence R. The effective use of combined modality therapy for the treatment of patients with Hodgkin's disease who relapsed following radiotherapy. American Journal of Clinical Oncology. 6: 313-318. PMID 6846249 DOI: 10.1097/00000421-198306000-00010 |
0.36 |
|
| 1983 |
Carr F, Medina W, Dube S, Bertino J. Genetic transformation of murine bone marrow cells to methotrexate resistance Blood. 62: 180-185. DOI: 10.1182/Blood.V62.1.180.Bloodjournal621180 |
0.31 |
|
| 1982 |
Newcomer LN, Cadman EC, Prosnitz LR, Farber LR, Bertino JR. Splenectomy in Hodgkin's disease: No therapeutic benefit American Journal of Clinical Oncology: Cancer Clinical Trials. 5: 393-397. PMID 7113962 DOI: 10.1097/00000421-198208000-00008 |
0.786 |
|
| 1982 |
Newcomer LN, Silverstein MB, Cadman EC, Farber LR, Bertino JR, Prosnitz LR. Bone involvement in Hodgkin's disease Cancer. 49: 338-342. PMID 7053832 DOI: 10.1002/1097-0142(19820115)49:2<338::Aid-Cncr2820490221>3.0.Co;2-I |
0.778 |
|
| 1982 |
Cadman E, Drislane F, Waldron JA, Farber L, Prosnitz L, Bertino JR. High-dose pulse chlorambucil: effective therapy for rapid remission induction in nodular lymphocytic poorly differentiated lymphoma. Cancer. 50: 1037-41. PMID 7049345 DOI: 10.1002/1097-0142(19820915)50:6<1037::AID-CNCR2820500603>3.0.CO;2-N |
0.785 |
|
| 1982 |
Newcomer LN, Nerenberg MI, Cadman EC, Waldron JA, Farber LR, Bertino JR. The usefulness of the Lukes-Collins classification in identifying subsets of diffuse histiocytic lymphoma responsive to chemotherapy Cancer. 50: 439-443. PMID 7046901 DOI: 10.1002/1097-0142(19820801)50:3<439::AID-CNCR2820500310>3.0.CO;2-P |
0.791 |
|
| 1982 |
Newcomer LN, Cadman EC, Nerenberg MI, Chen M, Bertino JR, Farber LR, Prosnitz LR. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma Cancer Treatment Reports. 66: 1279-1284. PMID 6177407 |
0.785 |
|
| 1981 |
Fernandes DJ, Bertino JR. 5-fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyridylate binding to thymidylate synthase by dihydropteroylpolyglutamates. Proceedings of the National Academy of Sciences of the United States of America. 77: 5663-7. PMID 6160578 DOI: 10.1073/Pnas.77.10.5663 |
0.302 |
|
| 1980 |
Farber LR, Prosnitz LR, Cadman EC, Lutes R, Bertino JR, Fischer DB. Curative potential of combined modality therapy for advanced Hodgkin's disease. Cancer. 46: 1509-17. PMID 7417953 DOI: 10.1002/1097-0142(19801001)46:7<1509::Aid-Cncr2820460702>3.0.Co;2-T |
0.785 |
|
| 1980 |
Rudnick SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer. 44: 1189-93. PMID 498009 DOI: 10.1002/1097-0142(197910)44:4<1189::Aid-Cncr2820440404>3.0.Co;2-O |
0.785 |
|
| 1979 |
Chen BK, Horváth C, Bertino JR. Multivariate analysis and quantitative structure-activity relationships. Inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines. Journal of Medicinal Chemistry. 22: 483-91. PMID 110930 DOI: 10.1021/Jm00191A005 |
0.308 |
|
| 1977 |
Lindquist CA, Cadman EC, Bertino JR. A fluorometric assay for dihydrofolate reductase. Analytical Biochemistry. 83: 20-5. PMID 920937 DOI: 10.1016/0003-2697(77)90504-8 |
0.757 |
|
| 1977 |
Cadman EC, Lunberg WB, Bertino JR. Hyperphosphatermia and hypocalcemia accompanying rapid cell lysis in a patient with Burkitt's lymphoma and Burkitt cell leukemia. The American Journal of Medicine. 62: 283-90. PMID 835606 DOI: 10.1016/0002-9343(77)90324-2 |
0.782 |
|
| 1977 |
Cadman EC, Capizzi RL, Bertino JR. Acute nonlymphocytic leukemia: a delayed complication of Hodgkin's disease therapy: analysis of 109 cases. Cancer. 40: 1280-96. PMID 409479 DOI: 10.1002/1097-0142(197709)40:3<1280::Aid-Cncr2820400343>3.0.Co;2-A |
0.795 |
|
| 1977 |
Bertino JR, Sawicki WL, Cashmore AR, Cadman EC, Skeel RT. Natural resistance to methotrexate in human acute nonlymphocytic leukemia. Cancer Treatment Reports. 61: 667-73. PMID 267508 |
0.765 |
|
| 1977 |
Cadman E, Bertino JR. Chemotherapy of skeletal metastases. International Journal of Radiation Oncology, Biology, Physics. 1: 1211-5. PMID 62744 DOI: 10.1016/0360-3016(76)90097-3 |
0.771 |
|
| 1976 |
Cadman EC, Lundberg WB, Bertino JR. Systemic methotrexate toxicity. A pharmacological study of its occurrence after intrathecal administration in a patient with renal failure. Archives of Internal Medicine. 136: 1321-2. PMID 990053 DOI: 10.1001/archinte.136.11.1321 |
0.765 |
|
| 1973 |
Prosnitz LR, Farber LR, Fischer JJ, Bertino JR. Low dose radiation therapy and combination chemotherapy in the treatment of advanced Hodgkin's disease. Radiology. 107: 187-93. PMID 4689429 DOI: 10.1148/107.1.187 |
0.338 |
|
| 1969 |
Hryniuk WM, Bertino JR. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. The Journal of Clinical Investigation. 48: 2140-55. PMID 5259150 DOI: 10.1172/Jci106181 |
0.369 |
|
| 1969 |
Perkins JP, Hillman G, Fischer D, Bertino JR. Antibody to dihydrofolate reductase from a methotrexate-resistant subline of the L1210 lymphoma. Molecular Pharmacology. 5: 213-8. PMID 4389029 |
0.725 |
|
| 1967 |
Perkins JP, Hillcoat BL, Bertino JR. Dihydrofolate reductase from a resistant subline of the L1210 lymphoma. Purification and properties. The Journal of Biological Chemistry. 242: 4771-6. PMID 4964810 |
0.728 |
|
| 1967 |
Hillcoat BL, Perkins JP, Bertino JR. Dihydrofolate reductase from the L1210 R murine lymphoma. Further studies on the binding of substrates and inhibitors to the enzyme. The Journal of Biological Chemistry. 242: 4777-81. PMID 4383525 |
0.731 |
|
| 1966 |
Johns DG, Sartorelli AC, Bertino JR, Iannotti AT, Booth BA, Welch AD. Enzymic hydroxylation of 5-fluoropyrimidines by aldehyde oxidase and xanthine oxidase Biochemical Pharmacology. 15: 400-403. PMID 5911552 DOI: 10.1016/0006-2952(66)90314-5 |
0.57 |
|
| 1966 |
Bertino JR, Iannotti AT, Perkins JP, Johns DG. Dihydrofolate reductase from guinea pig liver and small intestine. Biochemical Pharmacology. 15: 563-71. PMID 5227348 DOI: 10.1016/0006-2952(66)90023-2 |
0.704 |
|
| 1966 |
Perkins JP, Bertino JR. Dihydrofolate reductase from the L1210R murine lymphoma. Fluorometric measurements of the interaction of the enzyme with coenzymes, substrates, and inhibitors. Biochemistry. 5: 1005-12. PMID 4380350 DOI: 10.1021/bi00867a028 |
0.731 |
|
| 1965 |
PERKINS JP, BERTINO JR. INTERACTION OF ORGANIC MERCURIAL COMPOUNDS WITH DIHYDROFOLATE REDUCTASE FROM EHRLICH ASCITES CARCINOMA CELLS. Biochemistry. 4: 847-53. PMID 14337700 DOI: 10.1021/bi00881a008 |
0.713 |
|
| 1965 |
BERTINO JR, PERKINS JP, JOHNS DG. PURIFICATION AND PROPERTIES OF DIHYDROFOLATE REDUCTASE FROM EHRLICH ASCITES CARCINOMA CELLS. Biochemistry. 4: 839-46. PMID 14337699 DOI: 10.1021/bi00881a007 |
0.721 |
|
| 1963 |
BERTINO JR, SILBER R, FREEMAN M, ALENTY A, ALBRECHT M, GABRIO BW, HUENNEKENS FM. STUDIES ON NORMAL AND LEUKEMIC LEUKOCYTES. IV. TETRAHYDROFOLATE-DEPENDENT ENZYME SYSTEMS AND DIHYDROFOLIC REDUCTASE The Journal of Clinical Investigation. 42: 1899-1907. PMID 14090749 |
0.533 |
|
| 1963 |
Huennekens FM, Bertino JR, Silber R, Gabrio BW. Antimetabolites in the chemotherapy of leukemia Experimental Cell Research. 9: 441-461. PMID 14046245 |
0.568 |
|
| 1962 |
Bertino JR, Donohue DR, Gabrio BW, Silber R, Alenty A, Meyer M, Huennekens FM. Increased level of dihydrofolic reductase in leucocytes of patients treated with amethopterin Nature. 193: 140-142. PMID 13868435 DOI: 10.1038/193140a0 |
0.562 |
|
| Show low-probability matches. |
